T-CELL LYMPHOMAS
Clinical trials for T-CELL LYMPHOMAS explained in plain language.
Never miss a new study
Get alerted when new T-CELL LYMPHOMAS trials appear
Sign up with your email to follow new studies for T-CELL LYMPHOMAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to outsmart T-Cell lymphoma without chemo
Disease control Recruiting nowThis study tests a new combination of two drugs, GW5282 and golidocitinib, for people with T-cell lymphoma. The first part finds the safest dose, and the second part checks if the combo works better than standard chemotherapy. About 165 adults with newly diagnosed or treated lymp…
Matched conditions: T-CELL LYMPHOMAS
Phase: PHASE1, PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 10:09 UTC
-
New drug combo aims to control Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests the safety of combining two drugs, ruxolitinib and duvelisib, in people whose T- or NK-cell lymphoma has come back or stopped responding to treatment. About 70 participants will receive the drugs to find the best dose and see if the combination can co…
Matched conditions: T-CELL LYMPHOMAS
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC